Article
Cancer researchers question antitrust arguments against Illumina-Grail deal
Rating:
0.0
Views:
63
Likes:
1
Library:
1
U.S. and European antitrust enforcers want to unwind gene sequencing leader Illumina Inc's purchase of cancer test company Grail, saying the two would stifle competition in a critical area of medicine, but some cancer researchers say it's far too early to make that assessment.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value